Skip to main content
TLRY
NASDAQ Life Sciences

Tilray Swaps $6M of Convertible Debt for 1.38M Shares, Extending a Pattern of Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.425
Mkt Cap
$602.02M
52W Low
$3.67
52W High
$23.2
52W Position info
21% above low
Off High info
81% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

TLRY sits 21% above its 52-week low of $3.67.

Summary

Tilray Brands issued 1.38 million shares to retire $6 million of convertible notes, marking the third such exchange in two months and adding to shareholder dilution.


Key Events · Financing and Capital Events · TLRY

  • Debt-for-Equity Exchange

    To retire $6 million principal of its 5.20% Convertible Senior Notes due 2027, Tilray issued 1,377,334 shares at an implied conversion price of approximately $4.36 per share.

  • Dilution Impact

    The new shares represent about 0.23% of the outstanding common stock, adding to the dilution from prior exchanges in June that totaled over 4.2 million shares.

  • Recurring Pattern

    This marks the third debt-for-equity swap in two months, following exchanges of $6 million and $12 million in June, signaling a strategy of managing convertible debt through equity issuance rather than cash repayment.

  • Transaction Terms

    Conducted privately with existing noteholders under Section 3(a)(9) of the Securities Act, the exchange involved no commissions.


Analysis · TLRY · Life Sciences

In its third debt-for-equity swap in two months, Tilray exchanged $6 million of its 5.20% Convertible Senior Notes due 2027 for 1.38 million common shares. While the move trims debt, it deepens the dilution that has become a recurring theme. The implied conversion price of about $4.36 per share sits slightly below the current stock price, suggesting noteholders are willing to accept shares near market value to exit the debt. This ongoing preference for managing the balance sheet through dilution rather than cash repayment could weigh on the stock if the pattern persists.

At the time of this filing, TLRY was trading at $4.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $602M. The 52-week trading range was $3.67 to $23.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLRY - Latest Insights

TLRY
Jul 28, 2026, 5:03 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $4.09
Real-time Price: $4.42 info
Change: +$0.330 (+8%) info
Market Cap: $602.02M info
TLRY
Jul 28, 2026, 4:25 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.09
Real-time Price: $4.42 info
Change: +$0.335 (+8%) info
Market Cap: $602.02M info
TLRY
Jul 28, 2026, 4:13 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $4.42 info
Change: +$0.3241 (+8%) info
Market Cap: $602.02M info
TLRY
Jul 28, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.11
Real-time Price: $4.42 info
Change: +$0.310 (+8%) info
Market Cap: $602.02M info
TLRY
Jul 09, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.45
Real-time Price: $4.42 info
Change: -$0.028 (-0.63%) info
Market Cap: $602.02M info